American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BIO-PATH HOLDINGS, INC. (BPTH)

$0.00 +0.00% OTC: BPTH · 15-min delayed

BELLAIRE, Texas
Public · OTC: BPTH

$0Revenue · FY2018

-$9.9MNet income

BPTHOTC

About BIO-PATH HOLDINGS, INC.

BIO-PATH HOLDINGS INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: BPTH
Headquarters: BELLAIRE, Texas
Industry: Pharmaceuticals

Registry IDs

Ticker: BPTH OTC
SEC CIK: 1133818
EIN: 870652870
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Bio-path Holdings, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/bio-path-holdings-inc/"><img src="https://americancompanies.com/badge/bio-path-holdings-inc.svg" alt="Bio-path Holdings, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow BIO-PATH HOLDINGS, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2018: $0
Net income: -$9.9M
Total assets: $3.9M

Source: SEC EDGAR · updated Jun 8, 2026

OTC: BPTH

$0.00 +0.00%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.00 $0.10

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Bio-path Holdings, Inc. (BPTH) Stock Price

Reported a net loss of $9.9M in FY2018.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BIO-PATH HOLDINGS, INC..

Write a review

Newsroom

News about BIO-PATH HOLDINGS, INC.

Bio-Path Holdings Provides Clinical and Operational Update GlobeNewswire Inc. · 2025-06-03 · positive Bio-Path Holdings Provides 2025 Clinical and Operational Update GlobeNewswire Inc. · 2025-01-10 · positive Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients GlobeNewswire Inc. · 2024-12-11 · positive Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. · 2024-10-09 · positive Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference GlobeNewswire Inc. · 2024-09-03 · positive Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress GlobeNewswire Inc. · 2024-06-14

News & sentiment via Polygon.io

FAQ

Bio-path Holdings, Inc.: frequently asked questions

Is Bio-path Holdings, Inc. an American company?

Bio-path Holdings, Inc. is a US-based company headquartered in Bellaire, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Bio-path Holdings, Inc. headquartered?

Bio-path Holdings, Inc. is headquartered in Bellaire, Texas, United States.

Is Bio-path Holdings, Inc. publicly traded?

Yes — Bio-path Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol BPTH on the OTC.

What does Bio-path Holdings, Inc. do?

Bio-path Holdings, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore